Tesamorelin

FDA-approved context Growth Hormone In 1 protocol 3 sources

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to secrete growth hormone. It is FDA-approved for reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy and is being researched for potential cognitive benefits.

01Dosing reference

Amount

2 mg/day

Frequency

Once daily (subcutaneous injection)

Cycle

Continuous use as prescribed (fat may return if discontinued)

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

GHRH receptor binding

Binds to growth hormone-releasing hormone (GHRH) receptors in the anterior pituitary gland.

Growth hormone secretion

Stimulates the synthesis and pulsatile release of endogenous growth hormone (GH).

Lipid metabolism and body composition

Increased GH levels promote lipolysis, specifically targeting and reducing visceral adipose tissue.

03Human evidence

Significant reduction in visceral adipose tissue (VAT).

Phase 3 clinical trials in HIV patients with lipodystrophy showed an 18% reduction in VAT over 26 weeks of treatment.

Potential benefits in mild cognitive impairment.

A randomized, double-blind, placebo-controlled trial showed improved executive function and verbal memory in older adults with mild cognitive impairment.

04Preclinical evidence

Preservation of pulsatile GH secretion.

Animal models demonstrated that tesamorelin maintains the natural pulsatile release of GH, unlike direct exogenous GH administration.

Improved lipid profiles.

In vivo studies showed reductions in triglycerides and improvements in cholesterol metabolism.

05What is known vs. unknown

Reasonably established

FDA-approved for the treatment of HIV-associated lipodystrophy.
Stimulates endogenous growth hormone production rather than replacing it.
Effectively reduces visceral adipose tissue (belly fat).
May have neuroprotective effects and improve cognitive function in older adults.

Unknowns & limits

Long-term cardiovascular safety and effects on cancer risk remain under investigation.
Visceral fat often returns after discontinuation of the drug.
Efficacy and safety for weight loss in non-HIV populations are not fully established.

06Safety & regulatory context

Regulatory statusTesamorelin is FDA-approved under the brand name Egrifta for HIV-associated lipodystrophy. Common side effects include injection site reactions, arthralgia (joint pain), myalgia (muscle pain), and peripheral edema. It is contraindicated in patients with active malignancy, pregnant women, and those with a disrupted hypothalamic-pituitary axis. It may increase IGF-1 levels, requiring regular monitoring by a healthcare provider.

07Compared with Ipamorelin

Tesamorelin vs. Ipamorelin

Key difference

Tesamorelin is a GHRH analogue that directly mimics the body's GHRH, while Ipamorelin is a ghrelin receptor agonist (GHRP) that stimulates GH release through a different pathway.

When researchers discuss each

Tesamorelin is often discussed in the context of targeted visceral fat reduction and FDA-approved clinical use, whereas Ipamorelin is studied for its milder side effect profile and lack of cortisol/prolactin elevation in anti-aging contexts.

08Appears in protocols

💪 Growth Hormone Optimization Protocol

1-2 mg/dayDaily

09Glossary

Lipodystrophy

Abnormal distribution of body fat, often seen as a side effect of certain antiretroviral therapies.

GHRH (Growth Hormone-Releasing Hormone)

A hormone produced in the hypothalamus that stimulates the pituitary gland to release growth hormone.

Visceral Adipose Tissue (VAT)

Fat stored deep inside the belly, wrapped around the organs, which is metabolically active and linked to health risks.

10Knowledge check

Q1What is the primary mechanism of action of tesamorelin?

Q2For which condition is tesamorelin FDA-approved?

Q3Which documented limitation about tesamorelin's evidence is stated in the dossier?

Q4According to the dossier, how are tesamorelin and ipamorelin mechanistically contrasted?

Q5Which safety or regulatory statement about tesamorelin is specified in the dossier?

11Sources

More in Growth Hormone

See all

Sermorelin

Growth Hormone

FDA-approved context

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to naturally produce and release human growth hormone (hGH), making it a subject of research for age-related growth hormone decline, body composition, and vitality.

200-500 mcg/day

Hexarelin

Growth Hormone

Human clinical

Hexarelin is a potent, synthetic hexapeptide and growth hormone secretagogue (GHS) that stimulates the release of growth hormone. Research indicates it is one of the strongest GH-releasing peptides available, offering potential benefits for muscle growth, fat loss, and cardiovascular health without significantly increasing appetite.

100-200 mcg per dose

GHRP-6

Growth Hormone

Human clinical

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates the release of endogenous growth hormone from the pituitary gland. Research shows it can increase appetite, promote muscle growth, and aid in fat loss by mimicking the action of ghrelin.

100-300 mcg per injection

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.